| Literature DB >> 17298666 |
Antonio Orlacchio1, Paolo Calabresi, Adriana Rum, Anna Tarzia, Anna Maria Salvati, Toshitaka Kawarai, Alessandro Stefani, Antonio Pisani, Giorgio Bernardi, Paolo Cianciulli, Patrizia Caprari.
Abstract
BACKGROUND: Neuroacanthocytosis (NA) denotes a heterogeneous group of diseases that are characterized by nervous system abnormalities in association with acanthocytosis in the patients' blood. The 4.1R protein of the erythrocyte membrane is critical for the membrane-associated cytoskeleton structure and in central neurons it regulates the stabilization of AMPA receptors on the neuronal surface at the postsynaptic density. We report clinical, biochemical, and genetic features in four patients from four unrelated families with NA in order to explain the cause of morphological abnormalities and the relationship with neurodegenerative processes. CASEEntities:
Mesh:
Substances:
Year: 2007 PMID: 17298666 PMCID: PMC1805452 DOI: 10.1186/1471-2377-7-4
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Figure 1Pedigrees of families RM13, RM15, RM16, and RM23. Black squares (males) and circles (females) indicate individuals affected with NA. Unaffected individuals are not shaded. Diagonal slashes represent deceased individuals. * Indicates individuals with acanthocytosis and the selective alteration of the 4.1R protein of the erythrocyte membrane.
Densitometric analysis of the erythrocyte 4.1R protein
| Index of patients | 4.1R (%)* |
| IV:1 (RM23) | 3.8 ± 0.10 |
| IV :1 (RM16) | 2.8 ± 0.35 |
| IV :3 (RM15) | 3.3 ± 0.20 |
| IV:6 (RM13) | 3.6 ± 0.25 |
| Relatives | |
| IV:2 (RM23) | 3.2 ± 0.30 |
| III:5 (RM23) | 3.1 ± 0.20 |
| V:2 (RM16) | 3.0 ± 0.30 |
| Controls (n = 21) | 4.41 ± 0.40^ |
* Patient values expressed as mean ± SD (n = 3)
^Reference values expressed as mean ± SD; from n.21 healthy blood donors. The 4.1R content was considered low when it was below the reference values.
Figure 3Electrophoretic analyses of crude spectrin extracts from patients (a = IV:1 RM23; b = IV:1 RM16) and control (c).
Figure 2Electrophoretic analyses (SDS-PAGE) of erythrocyte membrane proteins from patients (a = IV:6 RM13; c = IV:1 RM16; d = IV:3 RM15; e = IV:1 RM23) and controls (b, f). MW = molecular weight standards.